Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (251-260 of 355) with videos related to

Pageof 36
Sort By:
Vaccine|October 27, 2012
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in BrazilLily Yin Weckx, Allison Thompson, Eitan Naaman Berezin, et al.
Vaccine|February 21, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccinationJacek Wysocki, Jerzy Brzostek, Henryk Szymański, et al.
Vaccine|February 24, 2023
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trialKevin Cannon, Jose F Cardona, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|September 15, 2021
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United StatesShelly Senders, Nicola P Klein, Erik Lamberth, et al.
Pediatrics|August 25, 2010
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlersSylvia H Yeh, Alejandra Gurtman, David C Hurley, et al.
Heart Rhythm|July 19, 2014
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantationFlorian Egger, Michael Nürnberg, Miklos Rohla, et al.
Vaccine|February 22, 2011
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccineJanusz Gadzinowski, Piotr Albrecht, Barbara Hasiec, et al.
Chembiochem : a European Journal of Chemical Biology|September 24, 2024
Cavity-Based Discovery of New Fatty Acid PhotodecarboxylasesStefan Simić, Marco Cespugli, Michael C Hetmann, et al.
Human Vaccines & Immunotherapeutics|October 11, 2018
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trialAllison R Thompson, Nicola P Klein, H Jackson Downey, et al.
Infectious Diseases and Therapy|January 30, 2025
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix<sup>®</sup> Vaccine When Given to Healthy Infants at 3 and 12 Months of AgeSusanna Koski, Federico Martinon-Torres, Mika Rämet, et al.
Pageof 36

Showing results (251-260 of 355) with videos related to

Sort By:
Pageof 36
Vaccine|October 27, 2012
A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in BrazilLily Yin Weckx, Allison Thompson, Eitan Naaman Berezin, et al.
Vaccine|February 21, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccinationJacek Wysocki, Jerzy Brzostek, Henryk Szymański, et al.
Vaccine|February 24, 2023
Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trialKevin Cannon, Jose F Cardona, Kari Yacisin, et al.
The Pediatric Infectious Disease Journal|September 15, 2021
Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United StatesShelly Senders, Nicola P Klein, Erik Lamberth, et al.
Pediatrics|August 25, 2010
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlersSylvia H Yeh, Alejandra Gurtman, David C Hurley, et al.
Heart Rhythm|July 19, 2014
High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantationFlorian Egger, Michael Nürnberg, Miklos Rohla, et al.
Vaccine|February 22, 2011
Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccineJanusz Gadzinowski, Piotr Albrecht, Barbara Hasiec, et al.
Chembiochem : a European Journal of Chemical Biology|September 24, 2024
Cavity-Based Discovery of New Fatty Acid PhotodecarboxylasesStefan Simić, Marco Cespugli, Michael C Hetmann, et al.
Human Vaccines & Immunotherapeutics|October 11, 2018
Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trialAllison R Thompson, Nicola P Klein, H Jackson Downey, et al.
Infectious Diseases and Therapy|January 30, 2025
A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix<sup>®</sup> Vaccine When Given to Healthy Infants at 3 and 12 Months of AgeSusanna Koski, Federico Martinon-Torres, Mika Rämet, et al.
Pageof 36